Clinical trials: Hospital Admission
COVID-19
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19…
- Trial name
- NCT04480424
- Testing
- GAMUNEX-C, Standard Medical Treatment
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Grifols Therapeutics LLC
Pressure Injury Prevention
Biatain Silicone Sacral for Pressure Injury Prevention in Hospital-admitted Patients at Risk
A post market clinical follow-up study investigating the safety of Biatain Silicone Sacral while used as prevention in hospital admitted patients at risk of developing a pressure injury.
- Trial name
- NCT05619003
- Testing
- Biatain Silicone Sacral dressing
- Where
- 3 sites in Denmark
- Volunteers
- 67 people
- Sponsor
- Coloplast A/S
Surgical Procedures, Elective
Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)
This study will compare the incidence of residual neuromuscular blockade in participants who undergo reversal of neuromuscular blockade with sugammadex compared to those who undergo reversal of neuromuscular blockade with usual…
- Trial name
- NCT01479764
- Testing
- Sugammadex, Neostigmine, Glycopyrrolate
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19 Infection
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study.
- Trial name
- E-APLICOV-PC (NCT05121740)
- Testing
- Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day
- Where
- 10 sites in Spain
- Volunteers
- 34 people
- Sponsor
- PharmaMar
Sickle Cell Disease, Vaso-occlusive Crisis
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD).
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
- Trial name
- NCT04927247
- Testing
- Inclacumab
- Where
- 59 sites in United States, Brazil and 12 more
- Volunteers
- 72 people
- Sponsor
- Pfizer
Heart Failure
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in…
- Trial name
- FREEDOM-HF (NCT03458325)
- Testing
- Furoscix Infusor
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- scPharmaceuticals, Inc.